

Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)

Technology appraisal guidance

Published: 22 October 2025

www.nice.org.uk/guidance/ta1105

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of clascoterone as a topical treatment for acne vulgaris in people 12 years and over. This is because Glenmark Pharmaceuticals has confirmed that it does not intend to make an evidence submission for the appraisal. Glenmark Pharmaceuticals' view, which it has corroborated in consultation with healthcare professionals and other relevant decision makers, is that an appraisal will not add value.

Information

If NHS organisations wish to consider clascoterone for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-7279-1